Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
As of Nov 16, 2026, ANDA 216150 (Aripiprazole), held by Hetero Labs Ltd Iii, was first approved by FDA on Nov 1, 2023, with 1 approved supplement and 0 published complete response letters.
First approved: Nov 1, 2023
Review: Standard
Supplements approved: 1
Complete response letters: 0
What It's For
From the FDA-approved label (Indications and Usage)
Aripiprazole oral solution is indicated for the treatment of:
Schizophrenia
Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder
Irritability Associated with Autistic Disorder
Treatment of Tourette’s Disorder Aripiprazole oral solution is an atypical antipsychotic. The oral formulations are indicated for:
Schizophrenia
Acute Treatment of Manic and Mixed Episodes associated with Bipolar I
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters.Drugs@FDA and FDA complete response letters